BACKGROUND: Minimally invasive hysterectomy is now used routinely for women with uterine cancer. Most studies of minimally invasive surgery for endometrial cancer have focused on low-risk endometrioid tumors, with few reports of the safety of the procedure for women with higher risk histologic subtypes. OBJECTIVE: The purpose of this study was to examine the use of and survival associated with minimally invasive hysterectomy for women with uterine cancer and high-risk histologic subtypes. STUDY DESIGN: We used the National Cancer Database to identify women with stages IeIII uterine cancer who underwent hysterectomy from 2010e2014. Women with serous carcinomas, clear cell carcinomas, and sarcomas were examined. Women who had laparoscopic or roboticassisted hysterectomy were compared with those who underwent open abdominal hysterectomy. After a propensity score inverse probability of treatment weighted analysis, the effect of minimally invasive hysterectomy on overall, 30-day, and 90-day mortality rates was examined for each histologic subtype of uterine cancer. RESULTS: Of 94,507 patients who were identified, 64,417 patients (68.2%) underwent minimally invasive hysterectomy. Among women with endometrioid tumors (n¼81,115), 70.8% underwent minimally
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inimally invasive hysterectomy has become the preferred surgical approach for the treatment of women with early-stage uterine cancer. 1e8 Compared with laparotomy, minimally invasive hysterectomy is associated with fewer complications, less postoperative pain and bleeding, and a shorter length of stay. 4, 9, 10 From an oncologic standpoint, several randomized controlled trials and large observational studies have shown that long-term outcomes and survival after minimally invasive hysterectomy are not inferior to abdominal hysterectomy. 1e3 Given the benefits of minimally invasive hysterectomy, the procedure has become the standard of care for endometrial cancer.
1e3 Use of minimally invasive hysterectomy for early-stage endometrial cancer has been proposed as a quality metric, and populationbased data have suggested that uptake of the procedure has been increasing rapidly. 11 However, despite these benefits, most studies of minimally invasive hysterectomy have focused on women with low-risk endometrial tumors. Patients with high-risk histologic subtypes have been excluded from many trials or represent only a small number of subjects in other studies. 2, 10 Theoretically, performance of minimally invasive surgery in women with high-risk histologic subtypes has a number of concerns. These patients often have larger tumors and uteri and are at higher risk for dissemination beyond the uterus. As such, women with high-risk histologic subtypes may be at higher risk for portsite metastases and tumor spillage and dissemination because of uterine manipulation and vaginal removal of the uterus during the procedure. Given the limited data describing the safety of minimally invasive hysterectomy for women with uterine cancer and high-risk histologic subtypes, we performed a population-based analysis to examine the outcomes of the procedure in these women. Specifically, we examined trends the use of minimally invasive hysterectomy and compared survival between abdominal and minimally invasive hysterectomy in women with stage IeIII nonendometrioid uterine cancers.
Methods

Data source and cohort selection
The National Cancer Database (NCDB) was used for analysis. NCDB is a nationwide registry that was developed by the American College of Surgeons and American Cancer Society. 12, 13 The database records all patients with newly diagnosed invasive cancers from >1500 Commission on Cancereaffiliated hospitals that are located throughout the United States. The NCDB catalogues Original Research ajog.org data on patient demographic factors, tumor characteristics and treatment data, staging, and survival. Data are abstracted by trained registrars and are audited regularly to ensure accuracy. It is estimated that the data for approximately 67% of women with invasive cancer in the Unite States are captured in the NCDB. 14 The study was deemed exempt by the Institutional Review Board of Columbia University.
Women with stage IeIII uterine cancer diagnosed from 2004e2014 were included. Only patients who underwent total hysterectomy and had a known route of hysterectomy were included in the analysis (Figure 1 ). The route of hysterectomy was classified as abdominal, laparoscopic, and robotic-assisted. Patients who underwent either a laparoscopic or robotic-assisted procedure were classified as having undergone minimally invasive surgery. The cohort was limited to those women with positive histologic confirmation of endometrioid, serous, clear cell, sarcoma, leiomyosarcoma, stromal sarcoma, and carcinosarcoma. Women with sarcomas without further classification as leiomyosarcoma, carcinosarcoma, or stromal sarcoma were categorized as a separate subgroup. Women who received radiation before surgery were excluded from the cohort.
Clinical characteristics and outcomes
Demographic data that were analyzed included age (<50, 50e59, 60e69, 
15,16
Tumor stage (stages IAeIIIC), tumor grade (well, moderate, poorly differentiated, or unknown), and tumor size (0e20, 21e40, 41e60, 61e80, 81e100, >100 mm, or unknown) was also noted for each patient. Treatment characteristics that included lymph node assessment (yes, no, unknown), use of chemotherapy (yes, no, unknown), and use of radiation (external beam with or without brachytherapy, brachytherapy, none) were recorded for each individual. Hospital characteristics were analyzed and categorized by regional location (Eastern, South, Midwest, West, unknown) and urban/rural location (metropolitan, urban, rural, unknown). Based on the American College of Surgeons criteria, hospitals were classified as academic/ research cancer centers or community cancer centers.
The primary endpoint of the analysis was survival. Short-term survival was estimated as 30-and 90-day survival. Overall survival was estimated as the time from diagnosis until death from any cause or the date of last follow-up observation.
Statistical analysis
We stratified demographic and clinical characteristics of women with endometrial cancer by route of hysterectomy (abdominal vs minimally invasive). Frequency distributions between categoric variables were compared with the use of c 2 tests. Multivariable log-linear regression models with Poisson distribution and log link based on a generalized estimating equation were developed to estimate the association between each covariate and the use of minimally invasive surgery after accounting for hospital clustering. The results are reported as adjusted rate ratios with 95% confidence intervals (CIs).
A propensity score analysis was used to limit the influence of measured confounders on survival. 17, 18 The propensity score was estimated as the predicted probability that a patient underwent a minimally invasive hysterectomy. The inverse probability of treatment weighting (IPTW) approach based on propensity score was used to balance the observed confounders between treatments (abdominal vs minimally invasive hysterectomy). To calculate the propensity score, we fit a logistic regression model that included all of the clinical, oncologic, and hospital characteristics and 2-way interaction terms. The predicted probability (the propensity score) that ranges from 0e1 was estimated for each patient. The weighting assumptions of the IPTW approach assigns patients who underwent the treatment of interest a weight of 1/propensity score and those who did not undergo the treatment of interest a weight of 1/(1-propensity score). To standardize the variability of IPTW and reduce the influence of extreme weights, we applied a stabilization that multiplies the weights from treatment and comparison groups by a constant and used a trimming technique that trims the stabilized weights within a specified range (10) . 19 
AJOG at a Glance
Why was this study conducted? Although minimally invasive surgery is used routinely for women with uterine cancer, most studies have focused on low-risk, endometrioid tumors with few studies of women with higher risk histologic subtypes.
Key findings
The rates of minimally invasive surgery in those women with nonendometrioid tumors was 57.6% for serous carcinomas, 57.0% for clear cell tumors, 47.3% for sarcomas, 32.2% for leiomyosarcomas, 47.9% for stromal sarcomas, and 48.5% for carcinosarcomas. There was no association between route of surgery and 30-day, 90-day, or overall deaths for any of the nonendometrioid histologic subtypes.
What does this add to what is known?
The use of minimally invasive surgery for women with stage IeIII nonendometrioid uterine tumors does not appear to impact survival adversely.
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After IPTW, the balance of measured confounders between treatments was assessed via a weighted regression approach, in which each covariate was regressed on the treatment variable. The coefficients and corresponding probability values in the weighted regression models were used to determine the clinically unimportant differences between treatment groups with the use of a threshold value of the coefficients of <0.2.
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Separate propensity scores models were developed for each histologic subtype with the use of backward selection. Individual models for endometroid cancer, serous carcinoma, and carcinosarcoma included all the main effects and 2-way interaction terms with a significance level of 0.2e0.1 to allow for model convergence. Given the smaller sample size of some of the histologic subtypes, models for clear cell carcinoma, sarcoma, leiomyosarcoma, and stromal sarcoma included all covariates without interaction terms. All propensity score models had acceptable model discrimination of C-statistics between 0.7 and 0.8 and provided a good fit to the data, based on Hosmer-Lemeshow goodness-of-fit tests. 21 After propensity score weighting, we compared 30-and 90-day mortality rates based on surgical approach by marginal log-linear regression models that accounted for inverse probability weight and lymph nodes dissection and hospital clustering. Marginal multivariable Cox proportional-hazard models were developed to evaluate the effect of surgical approach on overall survival. Along with performance of lymph nodes dissection, the use of chemotherapy and radiation were adjusted in the overall mortality model. Results from Cox proportional-hazard models were reported as adjusted hazards ratios with 95% confidence intervals. Kaplan-Meier curves were developed to assess survival based on use of minimally invasive hysterectomy compared with laparotomy. Separate curves were developed for each histologic subtype in the IPTW cohorts.
Results were compared with the use of log rank tests. Sensitivity analyses were performed to examine survival separately for each stage (stages I, II, III). All analyses were performed with SAS software (version 9.4; SAS Institute Inc, Cary, NC). All statistical tests were 2-sided. A probability value of <.05 was considered statistically significant. Among women with endometrioid tumors who underwent a minimally invasive hysterectomy, robotic-assisted procedures accounted for 68.3% of the cases in 2010 and rose over time to 77.1% by 2014 (Figure 3 ). Except for leiomyosarcomas, similar trends were noted for the other nonendometrioid histologic subtypes, with roboticassisted procedures accounting for 61.7e75.7% of the minimally invasive hysterectomies by 2014. For women with leiomyosarcomas, robotic assistance was used in <50% of the minimally invasive cases during most of the years of the study. ajog.org
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In a multivariable model, compared with endometrioid histologic evidence, patients with the other histologic subtypes were less likely to undergo minimally invasive hysterectomy (P<.0001 for all; Table 2 ). Patients with sarcoma and leiomyosarcoma histologic evidence were least likely to undergo minimally invasive surgery, with rate After propensity score weighting, the cohort was well balanced ( Table 2 ). The median follow-up time for patients with nonendometrioid tumors was 27.9 months (interquartile range, 17.4e41.5 months). For each of the nonendometrioid histologic subtypes, there was no statistically significant association between route of surgery and either 30-or 90-day mortality rate (Table 3) . Similarly, there was no association between route of surgery and overall mortality rate for any of the nonendometrioid histologic subtypes.
Similar findings were noted in a series of Kaplan-Meier analyses that were stratified by histologic data (P>.05 for all). The results were unchanged in a series of sensitivity analyses stratified by stage.
Comment
These findings demonstrate that the use of minimally invasive hysterectomy has increased rapidly for nonendometrioid uterine cancers. In addition to oncologic characteristics, a number of nonclinical factors are associated with the performance of minimally invasive hysterectomy. Importantly, for all of the nonendometrioid histologic subtypes examined, there was no association between the route of hysterectomy and survival. Despite the fact that data that support the efficacy of minimally invasive hysterectomy for women with nonendometrioid tumors are limited, our findings suggest that the procedure has already gained widespread acceptance among clinicians. By 2014, >50% of the hysterectomies performed for all of the histologic subtypes that we examined, except leiomyosarcoma, were performed via a minimally invasive surgical approach. Although diffusion of laparoscopic hysterectomy, which was first described in the 1990s, was initially slow, the use of the procedure has increased The widespread acceptance of minimally invasive hysterectomy for women with endometrioid tumors likely promoted the rise of the procedure for other histologic subtypes, despite the relative lack of data.
Minimally invasive surgery for highrisk nonendometrioid histologic subtypes presents the technical challenge of manipulating larger tumors with greater potential for metastatic spread. During the operation, increased intraabdominal pressure from carbon dioxide is required to maintain the pneumoperitoneum, often for a prolonged period; this pressure may increase the risk of abdominal wall metastases (so-called port-site metastases), which are estimated to occur in slightly >1% of women who undergo gynecologic surgery. 23 Also during the procedure, uterine manipulation may disrupt the uterine cavity and subsequently disseminate tumor cells into the vagina or through the fallopian tube. Large uteri, which are often associated with high-risk histologic evidence or more advanced disease, are particularly apt to result in tumor spillage during manipulation or removal through the vagina. This could affect both short-and long-term oncologic outcomes.
Previous studies that have examined the safety of minimally invasive hysterectomy for nonendometrioid tumors have included relatively small numbers of women. 2 The LAP2 trial included 492 women with nonendometrioid (clear cell, serous, sarcoma, and mixed) tumors. In subgroup analyses among women with nonendometrioid tumors, minimally invasive hysterectomy was found to be not inferior to laparotomy in all of the subtypes that were analyzed. 2 In contrast, the LACE trial excluded women with nonendometrioid histologic variants. 1, 10 Our findings are reassuring in that we found no difference in survival between laparotomy and minimally invasive hysterectomy in 30-or 90-day mortality rates or overall survival for women with serous and clear cell carcinoma, carcinosarcoma, and other uterine sarcomas. Robotic-assisted hysterectomy is now the most common minimally invasive surgical modality used in women with nonendometrioid tumors. For serous tumors and carcinosarcomas, robotically assisted procedures made up 3 quarters of the minimally invasive operations in our cohort. Studies of women with endometrioid tumors have also demonstrated rapid uptake of roboticassisted surgery. 24 Previous work has shown not only that outcomes are comparable between laparoscopic and robotic-assisted hysterectomy but also that robotic-assisted surgery is substantially more costly. 24 Although our study benefits from the inclusion of a large sample of patients, we recognize a number of important limitations. First, although the finding of no difference in survival was encouraging, our cohort was diagnosed from 2010e2014, and we cannot exclude the small possibility of a survival differential with longer follow-up period. Second, we lack data on some important clinical characteristics that include uterine size, tumor spillage at the time of surgery, and patterns of recurrence. Third, our data are based on tumor registry data, and we lack centralized pathology review. As such, there may be misclassification of a small number of women, particularly for those with uncommon histologic variants. Although perioperative complication rates have been compared for minimally invasive and open hysterectomy in a number of studies, there are few large studies limited to nonendometrioid uterine cancer. Although an analysis of complication rates is of interest, NCDB lacks detailed data on perioperative complications. Last, NCDB lacks data on toxicity, quality of life, and patient reported outcomes. As with any study of administrative data, we cannot capture individual patient and physician preferences that undoubtedly influenced treatment decision-making. However, from a patient standpoint, TABLE 3 Comparison of overall mortality rates and mortality rates within 30 or 90 days of surgery between treatments ajog.org GYNECOLOGY Original Research these outcomes have an important impact on medical decision-making and preferences and warrant future study. Because minimally invasive hysterectomy continues to diffuse into wider practice, monitoring outcomes of lessselected patients in real-world settings remains a priority. Although minimally invasive oncologic surgery has proved to be safe for a number of procedures, recent data for cervical cancer in which the mortality rate was higher for minimally invasive surgery highlights the importance of determining the comparative effectiveness of new procedures before widespread dissemination. 25 Our data suggest that minimally invasive hysterectomy for women with stage IeIII nonendometrioid uterine tumors does not affect survival adversely. Given the benefits of minimally invasive hysterectomy compared with laparotomy, the procedure appears to be a reasonable approach to the surgical treatment of women with nonendometrioid uterine cancers. n
